​​​​

 

 

Guidelines for the submission of documentation for single technology assessment (STA) of pharmaceuticalshttps://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/guidelines-for-the-submission-of-documentation-for-single-technology-assessment-sta-of-pharmaceuticalsGuidelines for the submission of documentation for single technology assessment (STA) of pharmaceuticalsThe guidelines were last revised in October 2021. 1933
Template for submission of documentation for the single technology assessment of pharmaceuticalshttps://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/template-for-submission-of-documentation-for-the-single-technology-assessment-of-pharmaceuticalsTemplate for submission of documentation for the single technology assessment of pharmaceuticalsDocumentation must be submitted in accordance with this templates and the submission guidelines. 1935
Guidelines for pre-meetings in connection with single technology assessments (STAs)https://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/guidelines-for-pre-meetings-in-connection-with-single-technology-assessments-stasGuidelines for pre-meetings in connection with single technology assessments (STAs)Pre-meetings with the Norwegian Medicines Agency (NoMA) are not obligatory, but may be arranged on request. 1936Information to companies seeking guidance.
Pharmaceuticals for which the Regulation on Medicinal Products grants exceptions from the documentation requirements for single technology assessments (STAs)https://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/pharmaceuticals-for-which-the-regulation-on-medicinal-products-grants-exceptions-from-the-documentation-requirements-for-single-technology-assessments-stasPharmaceuticals for which the Regulation on Medicinal Products grants exceptions from the documentation requirements for single technology assessments (STAs)​The following includes information on which pharmaceuticals that this concerns and the documentation that pharmaceutical companies must submit in order for the pharmaceutical to be assessed for public sector financing. 1937Information on which pharmaceuticals that this concerns and the documentation necessary in order to be assessed for public sector financing.
Access to pharmaceuticals for very small patient groups with extremely severe conditionshttps://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/access-to-pharmaceuticals-for-very-small-patient-groups-with-extremely-severe-conditionsAccess to pharmaceuticals for very small patient groups with extremely severe conditions​The Norwegian Medicines Agency has prepared a memorandum that describes arrangements for the single technology assessment (STA) of pharmaceuticals for such patient groups. 1938
FINOSEhttps://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/finoseFINOSEFINOSE is a prosess for joint assessment. ​The Nordic collaboration FINOSE offers efficient and transparent evaluations of medicinal products with a view to reimbursement or procurement in the four countries Denmark, Finland, Norway and Sweden.3544
Unit cost databasehttps://legemiddelverket.no/english/public-funding-and-pricing/documentation-for-sta/unit-cost-databaseUnit cost databaseThis is an overview of unit costs to facilitate the work in health technology assessments (HTAs) and submission of documentation. The unit cost database has been revised as of 07.12.2021.1939

Oppdatert: 22.10.2021

Publisert: 16.01.2019

​Fant du det du lette etter?